{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:56:39Z","timestamp":1774544199368,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"DOI":"10.7759\/cureus.41746","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T05:53:05Z","timestamp":1689141185000},"source":"Crossref","is-referenced-by-count":26,"title":["A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"FNU","family":"Jyotsna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Mahfooz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirath","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FNU","family":"Parshant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Simran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Harsha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Neha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dev","family":"Jyotishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipesh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirjana","family":"Subedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahima","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years","volume":"32","author":"Lawson CA","year":"2021","unstructured":"Lawson CA, Seidu S, Zaccardi F, et al.. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021, 32:100739. 10.1016\/j.eclinm.2021.100739","journal-title":"EClinicalMedicine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 aha\/acc\/hfsa guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 aha\/acc\/hfsa guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2022, 145:895-1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-019-00325-9","article-title":"Cardiovascular protection with anti-hyperglycemic agents","volume":"19","author":"Deedwania P","year":"2019","unstructured":"Deedwania P, Acharya T. Cardiovascular protection with anti-hyperglycemic agents. Am J Cardiovasc Drugs. 2019, 19:249-57. 10.1007\/s40256-019-00325-9","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0217","article-title":"Treatment of diabetic kidney disease: current and future","volume":"45","author":"Yamazaki T","year":"2021","unstructured":"Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of diabetic kidney disease: current and future. Diabetes Metab J. 2021, 45:11-26. 10.4093\/dmj.2020.0217","journal-title":"Diabetes Metab J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.005","article-title":"Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes","volume":"12","author":"Rossing P","year":"2022","unstructured":"Rossing P. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Kidney Int Suppl (2011). 2022, 12:27-35. 10.1016\/j.kisu.2021.11.005","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts","volume":"12","author":"Epstein M","year":"2022","unstructured":"Epstein M. Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts. Kidney Int Suppl (2011). 2022, 12:69-75. 10.1016\/j.kisu.2021.11.008","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal J","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022, 18:56-70. 10.1038\/s41581-021-00490-8","journal-title":"Nat Rev Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt B","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021, 385:2252-63. 10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris GL","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al.. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015, 314:884-94. 10.1001\/jama.2015.10081","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos G","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021, 143:540-52. 10.1161\/CIRCULATIONAHA.120.051898","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial","volume":"145","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation. 2022, 145:437-47. 10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama S","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, et al.. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017, 31:758-65. 10.1016\/j.jdiacomp.2016.11.021","journal-title":"J Diabetes Complications"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac024","article-title":"New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone","volume":"118","author":"Redon J","year":"2022","unstructured":"Redon J. New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone. Cardiovasc Res. 2022, 118:e36-7. 10.1093\/cvr\/cvac024","journal-title":"Cardiovasc Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu LC","year":"2015","unstructured":"Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015, 24:1123-35. 10.1517\/13543784.2015.1059819","journal-title":"Expert Opin Investig Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-008-0034-9","article-title":"Aldosterone and glomerular podocyte injury","volume":"12","author":"Nagase M","year":"2008","unstructured":"Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 2008, 12:233-42. 10.1007\/s10157-008-0034-9","journal-title":"Clin Exp Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama A","year":"2005","unstructured":"Nishiyama A, Yao L, Fan Y, et al.. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005, 45:710-6. 10.1161\/01.HYP.0000154681.38944.9a","journal-title":"Hypertension"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma EV","year":"2022","unstructured":"Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022, 15:501-13. 10.1080\/17512433.2022.2094770","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage P","year":"2016","unstructured":"Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016, 18:28-37. 10.1002\/ejhf.444","journal-title":"Eur J Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos G","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al.. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016, 37:2105-14. 10.1093\/eurheartj\/ehw132","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone","volume":"22","author":"Rico-Mesa JS","year":"2020","unstructured":"Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep. 2020, 22:140. 10.1007\/s11886-020-01399-7","journal-title":"Curr Cardiol Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei H","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e0254. 10.1097\/MD.0000000000010254","journal-title":"Medicine (Baltimore)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist L","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, et al.. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017, 69:870-8. 10.1161\/HYPERTENSIONAHA.116.08526","journal-title":"Hypertension"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170743-a-systematic-review-and-meta-analysis-on-the-efficacy-and-safety-of-finerenone-therapy-in-patients-with-cardiovascular-and-chronic-kidney-diseases-in-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:38Z","timestamp":1707509018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170743-a-systematic-review-and-meta-analysis-on-the-efficacy-and-safety-of-finerenone-therapy-in-patients-with-cardiovascular-and-chronic-kidney-diseases-in-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.41746","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}